INSTEM Announces Extension of Research Collaboration Agreement with U.S. FDA to 2031
Instem, a global SaaS leader for life‑science R&D, announced a five‑year extension of its Research Collaboration Agreement with the U.S. Food and Drug Administration, now running through February 2031. The partnership, originally launched in 2011, has become a cornerstone of FDA‑aligned computational toxicology work, allowing both parties to co‑develop tools that keep pace with emerging drug chemistries. By securing the agreement for another decade, Instem signals confidence in its Leadscope platform and reinforces its role as a trusted data partner for regulators. The extension also reflects the FDA’s broader strategy to partner with innovative technology firms, ensuring regulatory science benefits from cutting‑edge analytics across North America, Europe, and APAC.
UK-First AI Case-Finding Pathway Launched to Improve Early Detection of Oesophageal and Gastric Cancer
A new NHS‑first AI‑enabled case‑finding pathway has launched in North East Essex to detect oesophageal and gastric cancers earlier. The programme, built on the C the Signs platform, analyses routine electronic health records and patient‑reported data to flag high‑risk individuals....
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) From Merck Animal Health to Treat and Control Asian Longhorned Tick...
Merck Animal Health announced that the FDA has approved an expanded label for its once‑yearly injectable parasite control, Bravecto Quantum, adding treatment and control of Asian longhorned tick (Haemaphysalis longicornis) and Gulf Coast tick (Amblyomma maculatum) for 12 months. The product...
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
NeoGenomics announced that its PanTracer™ LBx liquid biopsy test has received Medicare coverage under CMS’s MolDX program. The CLIA‑certified assay profiles more than 500 genes, including MSI and blood‑tumor mutational burden, with a seven‑day turnaround. Coverage allows Medicare beneficiaries to...
UnitedHealthcare Expands Doula Offering to Employer-Sponsored Plans Nationwide
UnitedHealthcare announced a nationwide rollout of its Doula Support program for employer‑sponsored health plans, potentially reaching 7.2 million members by January 1, 2027. The benefit gives members the option to engage doulas in‑person or virtually throughout pregnancy, birth, and postpartum. UnitedHealthcare estimates its...
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-Severe Atopic Dermatitis
Almirall reported that lebrikizumab met both co‑primary endpoints in the Phase 3 ADorable‑1 trial, with 63% of pediatric participants achieving EASI‑75 and 44% attaining clear or almost clear skin (IGA 0/1) after 16 weeks. Key secondary outcomes showed significant itch reduction, higher...
L&T Technology Services Launches NVIDIA-Powered AI Lung Digital Twin Platform for Advanced Respiratory Diagnostics
L&T Technology Services (LTTS) unveiled an AI‑powered digital twin platform that creates immersive 3D models of patients’ lungs from CT scans. The solution leverages NVIDIA’s Physical AI stack—including Omniverse, TensorRT and MONAI—to deliver real‑time visualization, automated segmentation of airways, vessels...
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
Natera announced two peer‑reviewed studies demonstrating the clinical utility of its personalized ctDNA assay, Signatera, in anal squamous cell carcinoma and locally advanced rectal cancer. In the ASCC cohort of 84 patients, baseline negativity or clearance of ctDNA during chemoradiotherapy...
AHF Urges EU to Stop Blocking Health Equity
The AIDS Healthcare Foundation (AHF) Europe will stage an advocacy action and press conference in Brussels on March 18, 2026, urging the European Commission to adopt a legally binding Pathogen Access and Benefit‑Sharing (PABS) Annex to the WHO Pandemic Agreement. The organization...
RevnaBio Secures Triple International Laboratory Accreditation to Expand Precision Medicine and Clinical Research Infrastructure in Africa
RevnaBio received triple accreditation from the American Association for Laboratory Accreditation (A2LA) for ISO 15189, ISO 20387 and ISO/IEC 17043, validating its medical laboratory, biobanking and proficiency‑testing operations. The certifications boost diagnostic quality, enable local molecular testing, and provide a trusted platform for...
KERENDIA® (Finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
Bayer announced that Kerendia® (finerenone) met its primary endpoint in the Phase III FIND‑CKD trial, showing a statistically significant slowing of eGFR decline versus placebo in non‑diabetic chronic kidney disease patients. The study enrolled over 1,500 participants and represents the fifth...
Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-Acting Semaglutide
Samsung Bioepis and its sister firm Epis NexLab have signed a research collaboration and exclusive license agreement with G2GBIO to develop a long‑acting semaglutide formulation using G2GBIO’s proprietary microsphere technology. The deal grants Samsung Bioepis full rights to the semaglutide...
YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency...
YolTech Therapeutics announced FDA approval of its IND for YOLT-202, an in vivo adenine base‑editing therapy targeting Alpha‑1 Antitrypsin Deficiency. The clearance permits an open‑label, single‑dose Phase 2/3 expansion study across the U.S. and other regions. In the ongoing first‑in‑human trial,...
Advanced eClinical Training Expands Nationwide Clinical Partner Network, Strengthening Medical Assistant Workforce Pipeline
Advanced eClinical Training (ACT) announced that its clinical partner network now spans more than 1,000 healthcare sites across the United States, providing externship placements for students in its medical‑assistant, phlebotomy and allied‑health programs. The company’s extern‑to‑hire model lets providers evaluate...
ACCESS GPO Announces Preferred Strategic Commercial Agreement to Provide Affera™ Mapping and Ablation System with Sphere-9™ Catheter to Ambulatory Surgery...
ACCESS GPO has signed a multi‑year preferred agreement with Medtronic to supply the Affera™ Mapping and Ablation System, featuring the Sphere‑9™ catheter, to physician‑led ambulatory surgery centers across the United States. The partnership aims to accelerate adoption of pulsed field...
OpenFold Consortium Announces Major OpenFold3 Update and Public Release of Training Data for Reproducible Biomolecular AI
The OpenFold Consortium unveiled OpenFold3’s major update, releasing the full training datasets, model weights, code, and evaluation scripts via AWS’s Registry of Open Data. The open‑source co‑folding system now includes a dedicated portal with onboarding documentation and a public support...
Jackson Healthcare President Shane Jackson Honored on “Staffing 100” List of Leaders Shaping the Workforce Solutions Industry
Jackson Healthcare president Shane Jackson was named to the 2026 Staffing 100 North America list, marking his ninth consecutive appearance. During his tenure, the company added a dozen acquisitions, broadened its portfolio to include executive search, allied health, nursing, surgical services...
Western Alliance Bank Launches Healthcare Industry Specialization, Led by Industry Veteran Jennifer Hwang
Western Alliance Bank announced the launch of a dedicated Healthcare commercial banking team, headed by industry veteran Jennifer Hwang. The new unit will serve subsectors such as specialty pharmaceuticals, medical devices, home health, hospice, and ambulatory surgical centers. Leveraging the...
Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection
Aditxt, Inc. announced the acquisition of Ignite Proteomics for $36 million in Series A‑2 convertible preferred stock, adding a CLIA‑certified functional proteomics platform to its oncology portfolio. Ignite’s Reverse Phase Protein Array (RPPA) assay quantifies 32 phospho‑ and total‑protein biomarkers, offering therapy‑selection...
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should Be Accessible and...
Guardant Health released a Harris Poll showing 92% of Americans aged 45+ support no‑copay coverage for blood‑based colorectal cancer (CRC) screening. The survey highlighted anxiety around colonoscopies and disgust for stool tests as major barriers, while 77% said a FDA‑approved...
SoundHound at HIMSS26: How MUSC Health Turned a Staffing Crisis Into a Voice AI Success Story
SoundHound AI showcased its enterprise‑wide Amelia voice‑AI platform at HIMSS26, highlighting a massive deployment at MUSC Health. The system, branded Emily, has processed over 2.2 million calls across patient access, revenue cycle and pharmacy, automating one‑quarter of interactions and achieving a...
Heidi Arrives at HIMSS26 with R1 Partnership and a Platform Built Beyond the Scribe
Heidi used HIMSS26 to unveil its biggest product and partnership moves since launching its ambient AI scribe, announcing a revenue‑cycle integration with R1 and a new clinical‑evidence tool called Evidence. The company says the platform now handles over 2.7 million visits...
SS&C GlobeOp Hedge Fund Performance Index and Capital Movement Index
SS&C Technologies reported that its GlobeOp Hedge Fund Performance Index posted a 0.59% gross return for February 2026. The accompanying Capital Movement Index rose 0.87% in March, marking a 12‑month high of 129.47 points. The index, which tracks assets administered...
Heru Showcases PretestPro™ for the Heru VR-Powered Diagnostic Headset at Vision Expo
Heru unveiled PretestPro™ at Vision Expo, a VR‑powered diagnostic headset that completes four essential eye‑pre‑tests in under two minutes. The wearable platform merges visual field, near cover test, extraocular motility and quantitative pupillometry into a single, AI‑guided workflow, replacing multiple...
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
Alkermes plc announced the inaugural Alkermes Pathways APN Research Awards™, a competitive grant program offering up to $10,000 per project to licensed psychiatric‑mental health nurse practitioners researching schizophrenia or bipolar I disorder. The application window runs from March 16 to...
Baseimmune Announces Strategic Expansion Into Fibrosis with Lead Program Targeting Idiopathic Pulmonary Fibrosis (IPF)
Baseimmune announced a new fibrosis‑focused pipeline leveraging its computational protein design platform to create multi‑pathway immunotherapies, starting with idiopathic pulmonary fibrosis (IPF). The company aims to deliver proof‑of‑concept efficacy data for its lead IPF program in 2026‑2027, addressing the limitations...
Prodalim Strengthens Its Functional Platform to Enter the Fast-Growing Nutraceutical Market with the Acquisition of Sylvestre, a Market Leader in...
Prodalim announced the acquisition of Sylvestre, a Brazilian leader in botanical extracts, to bolster its functional ingredient portfolio. Sylvestre brings a catalog of more than 200 natural ingredients and advanced extraction capabilities. The deal accelerates Prodalim's push into the U.S....
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
Compass Pathways plc announced that its senior management will attend the Stifel 2026 Virtual CNS Forum on March 17‑18, 2026, and will take part in a fireside chat on March 18 at 10:30 am ET. The session will be streamed live...
Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets
Veristat announced an expansion of its regulatory and clinical‑trial services aimed at Chinese pharmaceutical and medical‑device companies seeking faster entry into European markets, as well as the United Kingdom, Switzerland, the United States, Canada and Australia. The CRO highlighted recent...
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive Β-Catenin:TCF Interaction, Receives FDA Orphan Drug Designation for...
Parabilis Medicines announced that the FDA has granted both Orphan Drug and Fast Track designations to zolucatetide, the first direct inhibitor of the β‑catenin:TCF interaction, for desmoid tumors. Early Phase 1/2 data showed a 100 % disease‑control rate in ten patients and...
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site
Chiesi Group and inhalation CDMO Bespak have expanded their long‑standing partnership by increasing pressurized metered‑dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel, UK site. The move supports Chiesi’s Carbon Minimal Inhaler (CMI) program, which targets up to a 90 %...
Kurin Prevails in Federal Appellate Court in Long-Running Litigation with Magnolia Medical Technologies
Kurin, Inc. secured a victory in the United States Court of Appeals for the Federal Circuit, which affirmed a district‑court ruling that its Lock technology does not infringe Magnolia Medical Technologies' patents. The appellate decision removes legal uncertainty and validates...
Aplantex and Investissement Québec Team up to Produce Molecules for the Cosmetic and Food Industries
Aplantex has partnered with Investissement Québec to use its state‑of‑the‑art demonstration plant for green biotechnology extraction. The collaboration gives Aplantex access to advanced equipment and technical experts, enabling faster refinement of plant‑based molecules with antioxidant, anti‑inflammatory, antimicrobial and anti‑aging properties....
Gene Therapy for Duchenne Muscular Dystrophy: Genethon Confirms Two-Year Efficacy in Patients Treated with Its Drug Candidate GNT0004 at Therapeutic...
Genethon presented two‑year data from its dose‑escalation phase showing that GNT0004, administered at 3 × 10¹³ vg/kg, produced sustained functional gains and biomarker improvements in ambulatory DMD boys. Motor scores rose 9 points on the NSAA, the 6‑minute walk distance improved by...
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples
Eurofins Biomnis has developed and validated a new LC‑MS/MS method to detect and quantify cereulide toxin in human stool samples. The assay meets ISO 15189 requirements, accounting for matrix effects, and delivers turnaround times suitable for routine clinical labs. Cereulide, linked...
Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
DexCom will unveil new real‑world evidence at ATTD 2026 showing its CGM improves HbA1c in non‑insulin‑treated Type 2 patients, reduces DKA‑related hospitalizations in Type 1 patients, and supports a safe Smart Basal insulin‑optimization system. The company also detailed a product roadmap featuring...
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema...
Curatis Holding and Japan’s Neupharma have signed an exclusive licensing deal granting Neupharma rights to develop and market corticorelin (C‑PTBE‑01) for peritumoral brain edema (PTBE) in Japan. The agreement includes up to CHF 83.5 million in upfront and milestone payments and royalties...
Bausch + Lomb Launches R&D “Teach-In” Webinar Series
Bausch + Lomb announced the kickoff of an R&D “Teach‑in” webinar series, beginning with a March 23 session focused on its glaucoma pipeline. Executive Vice President of R&D Yehia Hashad and senior leaders will discuss ELios™, an implant‑free laser glaucoma surgery already launched in...
HeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG...
HeartBeam Inc. announced that its executive team will attend three major investor and industry conferences in March 2026, including Oppenheimer’s virtual MedTech summit, the ROTH conference, and the American College of Cardiology’s ACC.26. The CEO and CFO will present a...
AN2 Therapeutics Announces $40 Million Private Placement Financing
AN2 Therapeutics announced a $40 million private placement, selling 8,245,611 common shares at $2.85 each and offering pre‑funded warrants for up to 5,789,493 additional shares. The placement, backed by Coastlands Capital, Commodore Capital, Vivo Capital and other investors, is slated to...
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
Pulse Biosciences reported long‑term results from its first‑in‑human nPulse Vybrance study, showing an average 74% reduction in benign thyroid nodule volume after 15‑22 months. The data, presented at the 2026 North American Society for Interventional Thyroidology meeting, revealed no nodule...
Bristol Myers Squibb Announces Positive Phase 3 Results From the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple...
Bristol Myers Squibb reported positive interim Phase 3 results from the SUCCESSOR‑2 study, showing that oral mezigdomide combined with carfilzomib and dexamethasone (MeziKd) significantly extended progression‑free survival versus carfilzomib‑dexamethasone alone in relapsed or refractory multiple myeloma. The trial marks the first...
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Daiichi Sankyo and AstraZeneca have received FDA priority review for ENHERTU® as a post‑neoadjuvant therapy in HER2‑positive early breast cancer. The decision follows the DESTINY‑Breast05 phase 3 trial, which showed a 53% reduction in invasive disease‑free survival events versus trastuzumab‑emtansine (T‑DM1). Three‑year...
Telestroke Services Market Projected to Reach $7.2 Billion by 2033 as Stroke Rates Rise and Rural Access Gaps Widen
Stroke incidence in the United States is climbing, with an 8% rise overall and a 15% surge among adults under 65, while neurologist wait times exceed three months. These trends create urgent demand for telestroke platforms that connect remote specialists...
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology
Mosaic Clinical Technologies announced that its AI unit Cognita received FDA Breakthrough Device Designation for Cognita Chest X‑Ray (CXR), the first generative vision‑language model in radiology to earn this status. The designation grants prioritized FDA interaction, potentially accelerating clearance. Internal...
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
GAIA and Daiichi Sankyo Europe announced an exclusive partnership to commercialize lipodia, a digital therapeutic for hypercholesterolemia, pending regulatory approval. The agreement gives Daiichi Sankyo exclusive rights in Germany with plans to expand across Europe, leveraging GAIA’s evidence‑based platform and Daiichi’s cardiovascular...
Tandem Mobi Now Compatible with Android Smartphones
Tandem Diabetes Care announced that its Tandem Mobi insulin pump is now compatible with Android smartphones in the United States via a newly released mobile app. The Android version received FDA clearance in November 2025 and entered a limited rollout in...
Harrison.ai Continues to Grow Open Platform Ecosystem, Welcomes Four New AI Partners
Harrison.ai announced that four AI companies—AIRAmed, Koios Medical, Lunit and Nanox AI—are joining its Open Platform, expanding the catalog of imaging solutions across X‑ray, CT, MRI, mammography and ultrasound. The platform maintains a vendor‑neutral, zero‑mark‑up model, allowing healthcare organizations to...
RecovryAI Announces FDA Breakthrough Device Designation for Patient-Facing Clinical AI
RecovryAI, emerging from stealth, received FDA Breakthrough Device Designation for its physician‑prescribed Virtual Care Assistants (VCAs), AI tools that guide patients through post‑operative recovery. The designation, reserved for devices that can substantially improve care standards, accelerates the company’s engagement with...
Resilience Care & InterSystems Partner to Streamline Oncology Care Pathways
InterSystems and Resilience Care have formed a technology partnership to integrate Resilience Care’s remote‑monitoring platform with InterSystems IRIS for Health, streamlining oncology care pathways. The integration layer connects hospital information systems, automates data exchange for chemotherapy, lab, and imaging appointments,...
